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Synopsis
Approximately one-third of cervical intraepithelial neoplasia 2 and above can be missed by only 
biopsying quadrants of the cervix with visible lesions by digital cervicography.
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HIV infection is associated with a higher incidence rate of cervical lesions and increased 
risk of cervical cancer [1]. New cervical cancer screening tests are available or in 
development, and many biomarkers hold promise for screening. It is important to evaluate 
the clinical performance characteristics of new screening tests in HIV-infected women, to 
inform possible introduction in this population. Histopathology is commonly used as the 
gold standard diagnosis in cervical cancer screening studies; however, verification bias can 
occur if none or only a subset of screen negatives receives histopathology. Verification bias 
results in an overestimation of sensitivity and underestimation of specificity of the screening 
test.
After receiving ethical approval from appropriate institutional bodies, 268 HIV-infected 
women accessing cervical cancer screening in Zambia were enrolled in the study [2]. Each 
woman provided written informed consent and was screened using cytology and visual 
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inspection with acetic acid coupled with digital cervicography (DC) [3]. Women with a 
lesion identified by DC received a biopsy from an area within the lesion most likely 
representing the most advanced degree of neoplasia, as well as a random biopsy from a 
quadrant without a lesion (if such a quadrant was present). Women with no visible lesions 
by DC received a random biopsy. Cervical disease was more advanced in biopsies from 
quadrants with visible lesions (Table 1), but approximately one-third of cervical 
intraepithelial neoplasia 2 and above (CIN2+) were from quadrants without lesions (17/55; 
31%), demonstrating that not all lesions are visible by DC. The results were stratified based 
on if one versus multiple cervical sites were sampled (Table 1). There was more disease in 
quadrants with visible lesions, but a substantial proportion of disease was identified in 
quadrants without visible lesions.
By obtaining a punch biopsy from cervical quadrants with and without visible lesions we 
estimated the amount of disease typically missed when biopsies are restricted to visible 
lesions. Approximately one-third of all CIN2+ were from quadrants without visible lesions, 
analogous to results by Pretorius et al. [4] who reported that 37% of all CIN2+ lesions in 
HIV-negative women were from colposcopically normal-appearing areas on the cervix. We 
recommend that screening studies include systematic sampling for histopathology regardless 
of the screening result, to minimize verification bias in cervical cancer screening trials.
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